Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Stanford University
University of Oklahoma
Stanford University
Albert Einstein College of Medicine
GOG Foundation
Roswell Park Cancer Institute
Eli Lilly and Company
GOG Foundation
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center